Results 331 to 340 of about 159,323 (346)

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

New England Journal of Medicine, 2018
David Adams, Alejandra Gonzalez-Duarte, Mitsuharu Ueda   +2 more
exaly  

Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis

New England Journal of Medicine, 2013
Teresa Coelho, David Adams, Pierre Lozeron   +2 more
exaly  

Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins

Lancet, The, 2003
Angela Dispenzieri, Morie A Gertz
exaly  

Primary amyloidosis

Clinical Radiology, 1964
openaire   +2 more sources

Primary Amyloidosis

Annals of Internal Medicine, 1968
W F, Barth, G G, Glenner, T A, Waldmann, R F, Zelis   +3 more
openaire   +2 more sources

Corneal Amyloidosis

American Journal of Ophthalmology, 1966
S D, McPherson, G T, Kiffney, C C, Freed
openaire   +3 more sources

Molecular Mechanisms of Amyloidosis

New England Journal of Medicine, 2003
Giampaolo Merlini, Vittorio Bellotti
exaly  

AMYLOIDOSIS: AN EXPRESSION OF IMMUNOLOGICAL TOLERANCE ?

Lancet, The, 1970
exaly  

Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis

Circulation, 2019
David Adams, Arnt V Kristen, Giampaolo Merlini   +2 more
exaly  

SECONDARY AMYLOIDOSIS

Annals of Internal Medicine, 1949
openaire   +2 more sources